HS-IRBs News May 2014

Health Sciences and Minimal Risk IRBs, IRB News / Volume 6, Number 5, May 2014

HS-IRBs Office Closed on Memorial Day

The HS-IRBs Office will be closed Monday, May 26th in observance of Memorial Day. The ARROW helpline also will not be staffed on May 26th.

Tips for Handling Study Team Transitions

With the end of the academic year upon us, some researchers may be leaving the UW. The following tips may be helpful in handling these study team transitions:
  • Update the List of Study Team Members: Study team members who are leaving the UW and will no longer be involved in the conduct of a study must be removed via a personnel or other change of protocol. For additional information, see Personnel Change Guidance .
  • Clarify IRB of Record Issues: UW-Madison IRB review does NOT automatically cover someone who leaves the UW, but continues to be involved in the conduct of a study open at the UW. Study teams who wish to keep someone on the study team after they leave the UW should contact asktheirb@medicine.wisc.edu for assistance.
  • Consider Whether a PI Change or Study Transfer Is Needed: Study teams may need to submit a change in PI if the current PI is leaving the UW or make arrangements for the PI to retain PI status at the UW for up to one year in order to complete the study. PIs leaving the UW also may wish to consider transferring IRB oversight for their study to another institution. For additional information, please see How do you change the responsible principal investigator (PI)? or email asktheirb@medicine.wisc.edu for assistance.

Consent Document Changes and Changes of Protocol

When submitting a change of protocol that includes revisions to the consent documents, please include the following information in the change of protocol form:

  • Will these changes result in suspension of enrollment for the study?
    • If not, be prepared to provide justification as to why a halt to enrollment is not necessary.
  • Will these changes require re-consent of study subjects (both those currently on study and those who have come off study)?
    • Even if no subjects have been enrolled AND enrollment is NOT being halted, study teams must still address whether re-consent is required as it is possible that subjects may be enrolled while the the change of protocol is under IRB review.
  • When addressing re-consent in the change of protocol form, keep the following in mind:
    • Provide a timeline for when subjects will be re-consented (e.g., at the next in-person study visit).
    • Study teams are generally expected to orally inform subjects of any new risk information prior to formal re-consenting. The study team should document this communication in the subject's research file.
    • If subjects are not re-consented within the time frame provided by the study team, a noncompliance report may be required.

The following is an example of language that could be used by study teams in the Informed Consent section of the Change of Protocol form:

“Enrollment to the study will not be halted while this change in risk information is being reviewed because we do not think the new risk information substantially alters the risks for subjects. The new information will be conveyed to study subjects orally, while we wait for the revised consent forms to be approved.  Once the revised consent forms are approved by the IRB we will formally re-consent study subjects at their next in-person study visit.  Subjects who are no longer on study do not need to be re-consented as this new risk information will not affect these participants (i.e., this risks are not late effects of the drugs).”

Please see Re-Consenting Subjects Guidance for additional information. 

ARROW Outage May 31st

ARROW will be offline for scheduled maintenance on Saturday, May 31st from 1PM to 5PM. We apologize for any inconvenience.

Questions? We're Here to Help!

Whether you have a question about a specific protocol, a general question about the submission process, or need clarification about research policy, we have several ways you can reach us.

  • For urgent issues (e.g., subject safety concerns), please call our main line (608-263-2362) and ask to speak with the staff reviewer on call for the day. Please do NOT use email for these kinds of questions.
  • For general IRB questions, please call our main line (608-263-2362) to speak with the staff reviewer on call or email asktheirb@medicine.wisc.edu. These are the quickest ways to get help with general questions.
  • For assistance with ARROW or technical questions, email askarrowirb@medicine.wisc.edu.
  • To receive the newsletter and other IRB updates, please sign up for the general HS-IRBs listserv by emailing join-hs_irbs_announcements@lists.wisc.edu.
  • To receive updates about WIRB, please sign up for the WIRB listsserv by emailing submitwirb@medicine.wisc.edu with a request to be put on the list.
  • Consultations: For investigators seeking assistance on a specific program or application, HS-IRBs staff are available for individual consultations. To request a consultation, complete the HS-IRBs Presentation and Consultation Request Form.
  • Presentations: The HS-IRBs office is available to provide the research community with presentations and trainings on a variety of topics. To request a presentation, complete the HS-IRBs Presentation and Consultation Request Form.

Keywords:newsletter, listserv, workshops, outage, leaving, transfer, irb of record, reconsent, re-consent, re-consenting   Doc ID:39989
Owner:Carol P.Group:Health Sciences IRBs
Created:2014-05-14 10:19 CDTUpdated:2015-06-09 16:14 CDT
Sites:Health Sciences IRBs
Feedback:  0   0